Pathophysiology of Pseudogout (CPPD)

Crystal Formation and Deposition Mechanism

• Elevated inorganic pyrophosphate levels are the central driver of CPP crystal formation in affected joints 1
• The American College of Rheumatology notes that CPP crystals accumulate primarily in fibrocartilage and hyaline cartilage of joints 1

Inflammatory Response

• Interleukin-1 (IL-1) appears to play a key role in the inflammatory cascade, which is why IL-1 inhibitors are being investigated as potential treatments 1, 2

Metabolic and Regulatory Factors

• Magnesium deficiency promotes CPP crystal formation, as magnesium normally solubilizes CPP crystals and inhibits their nucleation and growth 1, 3
• Medications like furosemide can precipitate CPPD by causing magnesium depletion 3
• Metabolic conditions including primary hyperparathyroidism, hemochromatosis, and hypomagnesemia predispose to CPPD development 4

Key Pathophysiologic Distinctions from Gout

• Unlike urate crystals in gout, there is currently no way to prevent CPP crystal formation or enhance their dissolution 1, 3
• The European League Against Rheumatism notes that this fundamental difference means CPPD treatment is restricted to symptomatic control rather than disease modification 1